Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hypocretin Receptor 2 Antagonism Dose-Dependently Reduces Escalated Heroin Self-Administration in Rats
Brooke E. Schmeichel, Estelle Barbier, Kaushik Misra, et al.
Neuropsychopharmacology (2014) Vol. 40, Iss. 5, pp. 1123-1129
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

The dark side of emotion: The addiction perspective
George F. Koob
European Journal of Pharmacology (2015) Vol. 753, pp. 73-87
Open Access | Times Cited: 409
Addiction and stress: An allostatic view
George F. Koob, Jay Schulkin
Neuroscience & Biobehavioral Reviews (2018) Vol. 106, pp. 245-262
Closed Access | Times Cited: 239
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
George F. Koob
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 163-201
Open Access | Times Cited: 233
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 114
The hypocretin (orexin) system: from a neural circuitry perspective
Shi‐Bin Li, Luı́s de Lecea
Neuropharmacology (2020) Vol. 167, pp. 107993-107993
Closed Access | Times Cited: 111
Existing and Future Drugs for the Treatment of the Dark Side of Addiction
George F. Koob, Barbara J. Mason
The Annual Review of Pharmacology and Toxicology (2015) Vol. 56, Iss. 1, pp. 299-322
Closed Access | Times Cited: 107
Orexins and fear: implications for the treatment of anxiety disorders
África Flores, Rocío Saravia, Rafaël Maldonado, et al.
Trends in Neurosciences (2015) Vol. 38, Iss. 9, pp. 550-559
Open Access | Times Cited: 92
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Neuroclinical Framework for the Role of Stress in Addiction
Laura E. Kwako, George F. Koob
Chronic Stress (2017) Vol. 1
Open Access | Times Cited: 78
Modeling the development of drug addiction in male and female animals
Wendy J. Lynch
Pharmacology Biochemistry and Behavior (2017) Vol. 164, pp. 50-61
Open Access | Times Cited: 71
Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine
Taylor A. Gentile, Steven J. Simmons, David J. Barker, et al.
Addiction Biology (2017) Vol. 23, Iss. 1, pp. 247-255
Open Access | Times Cited: 70
The role of orexin-1 receptor signaling in demand for the opioid fentanyl
Jennifer E. Fragale, Caroline B. Pantazis, Morgan H. James, et al.
Neuropsychopharmacology (2019) Vol. 44, Iss. 10, pp. 1690-1697
Open Access | Times Cited: 69
Male and female mice develop escalation of heroin intake and dependence following extended access
Eleanor Blair Towers, Brendan J. Tunstall, Mandy L. McCracken, et al.
Neuropharmacology (2019) Vol. 151, pp. 189-194
Open Access | Times Cited: 69
Intermittent self‐administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system
Jennifer E. Fragale, Morgan H. James, Gary Aston‐Jones
Addiction Biology (2020) Vol. 26, Iss. 3
Open Access | Times Cited: 65
Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats
Adam Kimbrough, Jenni Kononoff, Sierra Simpson, et al.
Psychopharmacology (2020) Vol. 237, Iss. 5, pp. 1545-1555
Open Access | Times Cited: 55
Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Morgan H. James, Jennifer E. Fragale, R. Nisha Aurora, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 5, pp. 717-719
Open Access | Times Cited: 51
Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors
F. Woodward Hopf
Neuropharmacology (2020) Vol. 168, pp. 108013-108013
Open Access | Times Cited: 50
Neural Substrates and Circuits of Drug Addiction
Matthew W. Feltenstein, Ronald E. See, Rita A. Fuchs
Cold Spring Harbor Perspectives in Medicine (2020) Vol. 11, Iss. 4, pp. a039628-a039628
Open Access | Times Cited: 50
Orexin Reserve: A Mechanistic Framework for the Role of Orexins (Hypocretins) in Addiction
Morgan H. James, Gary Aston‐Jones
Biological Psychiatry (2022) Vol. 92, Iss. 11, pp. 836-844
Open Access | Times Cited: 33
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Orexin-A/Hypocretin-1 Mediates Cocaine-Seeking Behavior in the Posterior Paraventricular Nucleus of the Thalamus via Orexin/Hypocretin Receptor-2
Alessandra Matzeu, Tony M. Kerr, Friedbert Weiss, et al.
Journal of Pharmacology and Experimental Therapeutics (2016) Vol. 359, Iss. 2, pp. 273-279
Open Access | Times Cited: 60
Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction
George F. Koob
Psychopharmacology (2017) Vol. 234, Iss. 9-10, pp. 1315-1332
Closed Access | Times Cited: 60
Compulsive-Like Sufentanil Vapor Self-Administration in Rats
Janaina C. M. Vendruscolo, Brendan J. Tunstall, Stephanie A Carmack, et al.
Neuropsychopharmacology (2017) Vol. 43, Iss. 4, pp. 801-809
Open Access | Times Cited: 60
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Drug addiction: An affective-cognitive disorder in need of a cure
Liana Fattore, Marco Diana
Neuroscience & Biobehavioral Reviews (2016) Vol. 65, pp. 341-361
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top